Form 4 for MRNA Moderna
Accepted 2025-12-15 00:00:00 ET · period of report 2025-12-11 · accession 0001682852-25-000094 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-15 | 2025-12-11 | MRNA | Bancel Stephane | CEO, Dir | M - OptEx | $10.90 | +688.1K | 6.18M | +13% | +$7.50M |
| D | 2025-12-15 | 2025-12-11 | MRNA | Bancel Stephane | CEO, Dir | M - OptEx | $0.00 | -688.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-11 | M | A | 688,073 | $10.90 | 6,181,970 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-12-11 | M | D | 688,073 | $0.00 | 0 | D | $10.90 · — to 2026-02-23 | 688,073 Common Stock | (F4) This option is fully vested and exercisable. |